Canopy Growth's September Vote Looms Large as Refinancing Buys Time for a Turnaround

Canopy Growth faces a pivotal shareholder vote on Sept 25 for a reverse split and bylaw changes, with quorum uncertainty and a recent refinancing providing breathing room.

Investors scanning Canopy Growth's recent price action might be forgiven for thinking the worst is over. The stock has clawed back roughly 12 percent over the past month, and the company's latest quarterly numbers showed a narrower-than-expected loss. But the real test arrives on September 25, when shareholders gather for an annual and extraordinary meeting that could reshape the company's capital structure — and, just as importantly, reveal whether it can even muster the votes to proceed.

The meeting agenda carries more weight than the usual slate of director elections and auditor reappointments. Management is seeking authorization for a voluntary reverse stock split, a new advance notice bylaw, and the issuance of unallocated awards under its compensation plan. A reverse split is, by definition, a mechanical exercise — it changes nothing about the underlying business. That the board feels compelled to put the option on the table, however, speaks volumes about how seriously it views the stock's prolonged slide.

There is a practical hurdle worth watching: Nasdaq rules require a quorum of 33? percent of voting shares. Given the company's shareholder base, whether that threshold gets reached is far from certain. A failed quorum would force a postponement, adding costs and delaying whatever structural decisions management wants to push through.

A Balance Sheet Breather

The September vote comes on the heels of a quieter but arguably more consequential financial maneuver. In March, Canopy Growth completed its acquisition of MTL Cannabis and replaced its prior first-lien credit facility with a secured term loan of $150 million. For a company that has spent years wrestling with its balance sheet, that refinancing is more than administrative housekeeping — it buys breathing room while operations continue to find their footing.

That breathing room matters because the operational picture, while improving, remains a work in progress. Net revenue for the first quarter of fiscal 2027, ended June 30, rose 13 percent year over year to C$81.2 million, with every business segment contributing to the advance. The figure came in just shy of the C$82.7 million consensus estimate compiled by FactSet, and the GAAP loss per share landed at C$0.03.

The quarter marked the first under CEO Luc Mongeau in which all segments grew on a year-over-year basis, with management attributing the gains to better cultivation practices, tighter cost controls, and early synergies from the MTL integration. International cannabis revenue climbed 10 percent, underpinned by European demand — a reminder of why the company's renewed EU-GMP certification for its Kincardine, Ontario facility, secured on August 14, matters. The certification, renewed by the Regierungspräsidium Tübingen, keeps the door open for Canadian-grown product to reach medical markets across Europe, a regulated niche where margins are more forgiving than the fiercely competitive recreational segment.

Guidance vs. Results

Management used the earnings call to sketch a path toward positive adjusted EBITDA in fiscal 2027, with sequential improvements to cannabis gross margin expected from the fourth quarter onward. The medium-term target calls for gross margin in the mid-to-upper 30 percent range once the MTL integration beds in. Those are ambitious goals — but they remain guidance, not reported results, and investors have been burned before by promises that outran delivery.

The market's ambivalence is visible in the chart. The stock closed Wednesday at €0.9036, more than a fifth above its 52-week low of €0.7500 hit in late March, yet still roughly 55 percent below its December high of €2.00. The shares have fallen 13 percent since the start of the year, and the 12-month decline stands at 29 percent. A 30-day realized volatility reading of 49 percent underscores just how bumpy the ride has been.

The company has also been busy with the quieter mechanics of corporate governance: proxy materials for the upcoming meeting went out on Monday, and a year-end report for fiscal 2026 was filed, with Reuters coverage noting that Canada's medical business has stabilized and the adult-use market is growing again. A late-August insider filing concerning Chief Legal Officer and Corporate Secretary Christelle surfaced without details — a minor footnote, but one that fits the pattern of a company adjusting on multiple fronts at once.

For now, the operational improvement edges out the structural question marks, but only just. The September meeting will show whether Canopy Growth can rebuild confidence through its own efforts — or whether it will need the cosmetic support of a reverse split to steady the ship. Either way, this remains a stock for investors with patience to spare and a high tolerance for volatility.